港股異動 | 獲投行唱好 新秀麗(1910.HK)反彈逾4% 此前3日連跌16%
格隆匯3月25日丨此前3連跌超16%的新秀麗(1910.HK)反彈4.3%,報14.52港元,暫成交8571萬港元,總市值208億港元。3月中旬新秀麗公吿,2020年股權持有人應占虧損約12.78億美元。野村指出,新秀麗去年度於成本控制方面見成效,加上環球旅遊業持續有改善,料其今年度業績有望扭虧為盈,而銷售料仍較2019年度下跌47%,至明年銷售有望回覆至2019年度的水平。該行將其目標價由14.4港元上調至21.6港元,維持買入評級。里昂將新秀麗目標價由16.4港元上調14.6%至18.8港元,維持“跑贏大市”評級。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.